• 1
    World Health Organization. Public health response to biological and chemical weapons. WHO guidance: 2001; 143213.
  • 2
    Khateri S. Statistical views on late complications of chemical weapons on Iranian CW victims. The ASA newsletter, No. 85, 31 August 2001; 1: 169.
  • 3
    Mazandarani M. Secretary-General of the Association for Helping Victims of Iraq's Chemical Warfare with Iran. Statement reported by the Islamic Republic News Agency, 1 December 1996.
  • 4
    Balali-Mood M, Balali-Mood K. Nerve agents. In: Brent J (ed.). Critical Care Toxicology. Elsevier Mosby, Philadelphia, PA, 2005;137993.
  • 5
    Balali-Mood M, Balali-Mood K. Neurotoxic disorders of organophosphorus compounds and their managments. Arch Iran Med 2008;11:6589.
  • 6
    Hilmas CJ, Smart JK, Hill BA.History of chemical warfare. Chapter 2 in Lenhart, MK, Editor-in chief (2008), Borden Institute: GPO, pg 62.
  • 7
    Casida JE, Quistad GB. Organophosphate toxicology: safety aspects of nonacetylcholinesterase secondary targets. Chem Res Toxicol 2004;17:98398.
  • 8
    Vassiliki A, Figueriredo H, Apland J, Qashu F, Braga FM, Braga M. Primary brain targets of nerve agents. Neurotoxicology 2009;30:772726. Epub 2009 Jul 8.
  • 9
    Newmark J. Nerve agents. Neurologist 2007;13:2032.
  • 10
    Sidell FR. Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates. Clin Toxicol (Phila) 1974;7:117.
  • 11
    Yaganisawa N, Morita H, Nakajima T. Sarin experiences in Japan: acute toxicity and long-term effects. J Neurol Sci 2006;249:7685.
  • 12
    Cannard K. The acute treatment of nerve agent exposure. J Neurol Sci 2006;249:8694.
  • 13
    Abdollahi M, Karami-Mohajeri S. A comprehensive review on experimental and clinical findings in intermediate syndrome by organophosphate poisoning. Toxicol Appl Pharmacol 2012;258:30914.
  • 14
    Balali-Mood M, Navaeian A. Clinical and paraclinical findings in 233 patients with sulfur mustard poisoning. In: Heyndrickx B (ed.). Proceedings of the Second World Congress on New Compounds in Biological and Chemical Warfare: Toxicological Evaluation. Ghent University Press, Ghent, Belgium, 1986; 46473.
  • 15
    Koc F, Yerdelen D, Kekec Z. Myeloneuritis due to acute organophosphate (DDVP) intoxication. Int J Neurosci 2009;119:153847.
  • 16
    Senanayake N, Karalliede L. Neurotoxic effects of organophosphorous insecticides. An intermediate syndrome. N Engl J Med 1987;316:7613.
  • 17
    Willems JL. Clinical management of mustard gas casualties. Ann Med Mil Belg 1989;3:S161.
  • 18
    Balali-Mood M, Hefazi M. The pharmacology, toxicology, and medical treatment of sulfur mustard poisoning. Fundam Clin Pharmacol 2005;19:297315.
  • 19
    Balali-Mood M, Hefazi M, Mahmoudi M, Jalali E, Attaran D, Maleki M, et al. Long-term complications of sulphur mustard poisoning in severely intoxicated Iranian veterans. Fundam Clin Pharmacol 2005;19:71321.
  • 20
    Emerick GL, Peccinini RG, de Oliveira GH. Organophosphorus-induced delayed neuropathy: a simple and efficient therapeutic strategy. Toxicol Lett 2010;192:23844.
  • 21
    Rickett D, Glenn J, Beers E. Central respiratory effects versus neuromuscular actions of nerve agents. Neurotoxicology 1953;8:46675.
  • 22
    Jokanović M, Kosanović M, Brkić D, Vukomanović P. Organophosphate induced delayed polyneuropathy in man: an overview. Clin Neurol Neurosurg 2011;113:710.
  • 23
    Peter JV, Prabhakar AT, Pichamuthu K. Delayed-onset encephalopathy and coma in acute organophosphate poisoning in humans. Neurotoxicology 2008;29:33542.
  • 24
    Watson AP, Jones TD, Griffin GD. Sulfur mustard as a carcinogen: application of relative potency analysis to the chemical warfare agents H, HD, and HT. Regul Toxicol Pharmacol 1989;10:125.
  • 25
    Balali-Mood M, Hefazi M. Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clin Pharmacol Toxicol 2006;99:27382.
  • 26
    Perrotta DM. Environment Committee Armed Forces Epidemiological Board long-term health effects associated with sub-clinical exposures to GB and mustard. Gulflink: Office of the Special Assistant for Gulf War Illnesses; 1996. Available at
  • 27
    Lotti M, Moretto A. Promotion of organophosphate induced delayed polyneuropathy by certain esterase inhibitors. Chem Biol Interact 1999;119–120:519524.
  • 28
    Abu-Qare AW, Abou-Donia MB. Sarin: health effects, metabolism, and methods of analysis. Food Chem Toxicol 2002;40:132733.
  • 29
    Nakajima T, Ohta S, Fukushima Y, Yanagisawa N. Sequelae of sarin toxicity at one and three years after exposure in Matsumoto, Japan. J Epidemiol 1999;9:33743.
  • 30
    Engel CC, Jaffer A, Adkins J, Riddle JR, Gibson R. Can we prevent a second ‘Gulf War syndrome’? Population-based healthcare for chronic idiopathic pain and fatigue after war Adv Pssychosom Med 2004;25:10222.
  • 31
    Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry 1997;62:3108.
  • 32
    Beghi E, Monticelli ML. Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation of risk factors by for polyneuropathy in The Two Italian Communities. Italian General Practitioner Study Group (IGPST). J Clin Epidemiol 1998;51:697702.
  • 33
    Forestier N, Bouche P. Neuropathies in the elderly: causes and practical driving. Cytokine Aging 2006;4:10919.
  • 34
    Imreova H, Pura M, Cesk CL. Differential diagnosis of peripheral neuropathy. Cas Lek Cesk 2005;144:62833; discussion 633–5.
  • 35
    Amirzargar MA, Yavangi M, Rahnavardi M, Jafari M, Mohseni M. Chronic mustard toxicity on the testis: a historical cohort study two decades after exposure. Int J Androl 2009;32:4116.
  • 36
    Ghanei M, Rajaee M, Khateri S, Alaeddini F, Haines D. Assessment of fertility among mustard-exposed residents of Sardasht, Iran: a historical Cohort study. Reprod Toxicol 2004;18:6359.
  • 37
    Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol 2010;49:23948.
  • 38
    Page WF. Long-term health effects of exposure to sarin and other anticholinesterase chemical warfare agents. Mil Med 2003;168:23945.
  • 39
    Craig AB, Freeman G. Clinical Observations on Workers Accidentally Exposed to “G” Agents. Medical Research Laboratory, Edgewood Arsenal, MD, 1953. Medical Laboratory Research Report 154.
  • 40
    Brody BB, Gammill JF. Seventy-five Cases of Accidental Nerve Gas Poisoning at Dugway Proving Ground. Medical Investigational Branch, Dugway Proving Ground, UT, 1954. Medical Investigational Branch Special Report 5.
  • 41
    Young JF, Gough BJ, Suber RL, Gaylor DW. Correlation of blood cholinesterase levels with toxicity of sarin in rats. J Toxicol Environ Health 2001;62:16174.
  • 42
    Newmark J. Nerve agents: Pathophysiology and treatment of posoning. Semin Neurol 2004;24:18596.
  • 43
    Duffy FH, Burchfiel JL, Bartels PH, Gaon M, Sim VM. Long-term effects of an organophosphate upon the human electroencephalogram. Toxicol Appl Pharmacol 1979;47:16176.
  • 44
    Holisaz MT, Rayegani SM, Hafezy R, Khedmat H, Motamedi MH. Screening for peripheral neuropathy in chemical warfare victims. Int J Rehabil Res 2007;30:714.
  • 45
    Wang L, Liu YH, Xu Y, Yin W, Huang YG. Thirteen-year follow-up of patients with tri-ortho-cresyl phosphate poisoning in northern suburbs of Xi'an in China. Neurotoxicology 2009;30:10847.
  • 46
    Wadia RS, Chitra S, Amin RB, Kiwalkar RS, Sardesai HV. Electrophysiological studies in acute organophosphate poisoning. J Neurol Neurosurg Psychiatry 1987;50:14428.
  • 47
    World Health Organization. Preventing and Managing the Global Epidemic: Report of WHO Consultation on Obesity. WHO, Geneva, 1998.